AstraZeneca delays clinical trials for COVID-19 vaccine  

AstraZeneca cancels clinical trials for COVID-19 vaccine  because a volunteer  for the vaccine had a side effect.

As part of the ongoing randomized, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial. This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials. Source AstraZeneca

Pascal Soriot, Chief Executive Officer, said: “At AstraZeneca we put science, safety and the interests of society at the heart of our work. This temporary pause is living proof that we follow those principles while a single event at one of our trial sites is assessed by a committee of independent experts. We will be guided by this committee as to when the trials could restart, so that we can continue our work at the earliest opportunity to provide this vaccine broadly, equitably and at no profit during this pandemic.”

(AZN) AstraZeneca PLC (AZN) NYSE – closed AT 53.64-1.07 (-1.96%) 4:00PM EDT, in afterhours trading the stock rose 54.05 +0.41 (0.76%)

 

A COVID-19 vaccine needs the public’s trust – and it’s risky to cut corners on clinical trials, as Russia is

FDA grants authorization for COVID-19 5 minute test and why this is good news for AYTU

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: